After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its ...
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...
23h
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...
Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...
US biotech company Sage Therapeutics is to slash a third of its remaining jobs - just a year after cutting 40% of its prior workforce.
Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...
Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s ...
Pomerantz LLP announces that a class action lawsuit has been filed against EngageSmart, Inc. ("EngageSmart" or the "Company") . Such investors are advised to contact Danielle Peyton at ...
In a new study examining people with opioid or alcohol use disorder, prescriptions for Ozempic, Wegovy, Mounjaro, and ...
Pomerantz LLP announces that a class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards" or the "Company") . Such investors are advised to contact Danielle Peyton at ...
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease. The decision, prompted by a ...
It’s been a whirlwind year for Joerg Moeller, M.D. After being appointed CEO of BenevolentAI in January, Moeller is now out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback